| Value | ₹28,163 Cr |
|---|
BSE filing, NSE: CIPLA. Summary written from the filing by ALFA Finder's alert engine.
Cipla Ltd: key numbers
- Share price
- ₹1,358.00
- Market cap
- ₹1,09,709 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 37.9×Sector 46.1×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Earnings Call Transcript: Key Takeaways
Cipla delivered record India revenue and margin expansion, masking high-stakes US product approval dependencies.
- Call
- Guides 20% growth
Cipla Employee Stock Options
Cipla granted 8,679 stock options and 27,140 ESARs to employees under its 2013 and 2021 schemes. Exercise price is INR 2 per option with graded vesting.
Cipla Management Change
Cipla's Board appointed Ms. Rashmi Joshi as additional Independent Director for 5 years. This strengthens the board's governance and financial oversight capabilities.
Cipla Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue INR 7,404 Cr (-2.4% YoY), EBITDA INR 1,388 Cr (18.7% margin), PAT INR 878 Cr (11.9%). Record quarterly India revenue; licensing deals in oncology biosimilars and ADCs.
Cipla Results Update
Cipla reported Q2FY27 consolidated revenue of ₹7,404 Cr and PAT of ₹878 Cr. EBITDA margin expanded 200 bps QoQ to 18.7%, with One-India growing 12% YoY.
Cipla Q2 FY27 Results: Net Profit ₹851.5 Cr, Down 37.1% YoY
Cipla Ltd reported revenue from operations of ₹7,404 Cr (-2.4% YoY) and net profit of ₹851.5 Cr (-37.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹851.5 Cr · -37.1% YoY
Other results update announcements
All →Indostar Capital Finance Results Update
IndoStar reported Q2 FY27 standalone results, with disbursements up 51% YoY to ₹1,399 crore. Profit after tax rose to ₹13.1 crore and AUM reached ₹8,459 crore.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Asset Reconstruction Company (India) Results Update
ARCIL's H1FY27 release shows total income up 48% to Rs.516.4 crore and PAT up 54% to Rs.290.0 crore. Investors should view performance over a longer horizon.
Capital Small Finance Bank Results Update
Capital SFB's Q2 FY27 PAT rose 30.7% year-on-year to ₹45.61 crore, while advances grew 23.4%. Asset quality improved, with GNPA at 2.36% and NNPA at 1.12%.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Fiberweb (India) Results Update
Fiberweb India's Q2 FY27 press release shows total income of ₹30.99 crore, up 209.36% quarter-on-quarter. Net profit rose to ₹1.27 crore.